Skip to main content

Table 4 EGFR and ERBB2 quantitative RT-PCR mRNA results in eight patients and matched controls (group B)

From: Erratum to: Increased copy number at 3p14 in breast cancer

Patient number

T

NN

T/NNa

1b

   

   EGFR

4,677

12,493

0.37

   ERBB2

24,066

21,817

1.1

2b

   

   EGFR

3,321

14,519

0.22

   ERBB2

61,389

6,666

9.2

4

   

   EGFR

20,778

14,842

1.39

   ERBB2

9,143

6,742

1.35

5b

   

   EGFR

9,730

15,867

0.61

   ERBB2

13,506

3,056

4.41

6

   

   EGFR

1,305

15,871

0.08

   ERBB2

10,677

10,080

1.06

7

   

   EGFR

1,024

12,162

0.08

   ERBB2

7,639

5,871

1.30

8b

   

   EGFR

4,936

28,111

0.17

   ERBB2

17,106

9,263

1.85

9

   

   EGFR

5,540

1,437

3.85

   ERBB2

7,330

5,540

1.32

  1. aT/NN: mRNA expression levels of EGFR/ERBB2 in tumour tissue (T) samples divided by values in in matched non-neoplastic (NN) tissue samples. As described in the results, at p.9, ratios > 1. 2 are regarded as significant overexpression and ratios < 0. 8 are regarded as significant underexpression in neoplastic tissue compared to non-neoplastic tissue. bPatients with increased LRIG1 copy number. No RNA from patient 3 was available for EGFR/ERBB2 analysis.